ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center.
Lisa B E Shields et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.